Rigel Pharmaceuticals Achieves Revenue Growth and Advances Clinical Pipeline for 2026

Rigel Pharmaceuticals Reports Strong Revenue Growth and Focus on Clinical Advancements

Rigel Pharmaceuticals, Inc. demonstrates impressive financial performance in its preliminary fourth quarter of 2025, revealing total revenue of approximately $69.8 million, a significant rise from $57.6 million in the same quarter of 2024. The company's net product sales amount to $65.4 million, showcasing a robust increase from $46.5 million year-over-year. This growth is largely attributed to the strong market performance of its key products: TAVALISSE®, which generated $45.6 million, GAVRETO® with $10.2 million, and REZLIDHIA® contributing $9.6 million. The sales figures reflect Rigel's successful portfolio strategy and its ability to meet the needs of patients with hematologic disorders and cancer.

In addition to product sales, Rigel Pharmaceuticals reports $4.4 million in contract revenues, further solidifying its financial foundation. The company's leadership is optimistic about future growth, with CEO Raul Rodriguez emphasizing the importance of 2025 as a year of substantial progress, including $77 million in cash generation. Looking ahead, Rigel forecasts total revenue for 2026 to be between $275 million and $290 million, with net product sales estimated at $255 million to $265 million. This optimistic outlook indicates the company’s strategic focus on scaling its operations and enhancing its product offerings in the coming year.

Rigel Pharmaceuticals is also making strides in its clinical developments, particularly with R289, currently undergoing a Phase 1b study for lower-risk myelodysplastic syndromes (MDS). The early results indicate that R289 is generally well tolerated, with a 33% response rate in transfusion-dependent patients at a dosage of 500 mg once daily, and a 40% response rate in the 500 mg twice-daily group. Rigel is set to complete enrollment in the dose expansion phase of the study and plans to recommend a Phase 2 dose by the latter half of 2026, showcasing the company's commitment to advancing innovative treatments in hematologic disorders.

In summary, Rigel Pharmaceuticals' strong revenue growth highlights its effective commercial strategy and solidifies its position in the biotech sector. With a clear focus on clinical advancements and a promising pipeline, the company is poised for continued success in 2026. The combination of financial performance and ongoing research efforts underscores Rigel’s dedication to improving patient outcomes in the challenging landscape of hematologic disorders and cancer treatments.